Sepsis in immunocompromised patients – New review sheds light on diagnostic challenges and future therapies
A comprehensive new review in The Lancet Respiratory Medicine, co-authored by our Marcin Osuchowski, Head of Sepsis-Trauma-Shock Research, brings together leading voices in the field to outline a roadmap for improving outcomes in one of sepsis medicine’s most vulnerable populations.
The authors explore why sepsis remains difficult to detect and treat in immunocompromised patients. From atypical symptoms to altered biomarker profiles, these patients face a higher risk of complications. Yet they remain underrepresented in clinical trials which impedes further knowledge gain.
“As sepsis is never the same across different patients, so is the immunosuppression type that affects them. Presence of immunosuppression in septic patients is a serious confounding factor. A sort of an elephant in the room – nobody wants him there but must be dealt with”, says Dr Osuchowski.
The paper highlights the need for tailored diagnostics, better understanding of immune dysfunction, and targeted therapies. The paper strongly argues for a shift away from one-size-fits-all definitions of immunosuppression in favour of individual immune profiling as the most promising path to improved interventions. Read the full article here.
